Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Bio’s lead candidate EB613, an oral tablet for osteoporosis, was selected for a Late Breaking Oral Presentation at the ENDO 2026 annual meeting. The presentation highlights new clinical data from a Phase 2 study of 161 postmenopausal women, which met both primary and secondary endpoints. This data supports the selection of a single EB613 tablet formulation for the company’s planned Phase 3 study.
Key figures
- Drug Name
- EB613
- Phase Of Trial
- Phase 2
- Study size
- 161
- Endpoints met
- primary (PD/bone turnover biomarker) and secondary (BMD)
- Study population
- postmenopausal women with osteoporosis
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.